Table VII.

Relationship between KIF3A expression and clinical pathological parameters in the140 cases by final score.

	Final score
Item	0	1	2	3	No.	P-value
Age						0.465
≤53	6	18	26	30	80
>53	2	14	26	18	60
Pathology grade						0.001a
G I	3	6	3	0	12
G I–II	0	4	13	5	22
G II	4	21	32	38	95
G III	0	1	3	3	7
ER						0.008a
Positive	5	15	39	24	83
Negative	2	15	9	21	47
PR						0.135
Positive	3	10	29	20	62
Negative	2	20	20	25	67
AR						0.309
Positive	7	19	37	37	100
Negative	1	13	15	11	40
HER2						0.344
Positive	2	7	14	19	42
Negative	5	23	35	26	89
Lymph node metastases						0.218a
TnN0	5	8	21	20	54
TnNn	3	23	31	27	84
P53						0.125
Positive	2	22	29	33	86
Negative	5	9	19	13	46
Ki-67						0.023a
−	2	6	10	6	24
+	4	19	29	23	75
++	1	3	8	10	22
+++	0	2	1	7	10
Ck56						0.872
Positive	0	4	8	7	19
Negative	7	26	40	39	112
EGFR						0.054
Positive	6	28	38	30	102
Negative	2	4	14	17	37
TN						0.873
TNBC	0	3	8	7	18
NTNBC	3	17	43	40	103

^aP<0.05

^bP<0.001. KIF3A, Kinesin Family Member 3A; ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; HER2, human epidermal growth factor receptor 2; EGFR, epidermal growth factor receptor; TN, triple-negative; TNBC, triple-negative breast cancer; NTNBC, non-triple-negative breast cancer.